Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 31

Sort by

Sort Order Select

Journal Articles

Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities

Blood (2024) 144 (Supplement 2): LBA-5.

https://doi.org/10.1182/blood-2024-212967

Published: 2024

Journal Articles

ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Blood (2024) 144 (Supplement 1): 409.

https://doi.org/10.1182/blood-2024-200867

Published: 2024

Journal Articles

Leg Ulcers in Sickle Cell Disease Patients Undergoing Hydroxyurea Therapy: Insights from Two Large Cohort Studies

Anoosha Habibi, Maryse Etienne-Julan, Emmanuelle Bernit, Maria Dimopoulou, Pagona Flevari, Ersi Voskaridou, Narcisse Elenga, Estelle Jean-Mignard, Giovanna Cannas, Pablo Bartolucci

Blood (2023) 142 (Supplement 1): 2500.

https://doi.org/10.1182/blood-2023-178198

Published: 2023

Journal Articles

Puberty Onset and Preservation of Fertility in Male Patients with Sickle Cell Disease Treated with Hydroxyurea: Data from the European Sickle Cell Disease Cohort - Hydroxyurea Extension (ESCORT-HU Extension) Study

Mariane De Montalembert, Pablo Bartolucci, Gonzalo De Luna, Anoosha Habibi, Scylia Alexis-Fardini, Maryse Etienne-Julan, Gylna Loko, Giovanna Cannas, Jean-Benoit Arlet, Latifatou Boukari, Sylvain Le Jeune, Laure Joseph

Blood (2023) 142 (Supplement 1): 145.

https://doi.org/10.1182/blood-2023-178219

Published: 2023

Journal Articles

Double-Blind Randomized Study to Evaluate the Effect of Hydroxycarbamide on Albuminuria in Adults with Sickle Cell Disease: Sikamic (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

Saliou Diop, Aldiouma Guindo, Gonzalo De Luna, Aurélien Yapi, Giovanna Cannas, Maryse Etienne-Julan, Jean-Benoit Arlet, Stephanie Ngo, Emmanuelle Bernit, Justine Gellen-Dautremer, Gylna Loko, Stanislas Nimubona, Anoosha Habibi, Vincent Audard, Pablo Bartolucci

Blood (2023) 142 (Supplement 1): 1157.

https://doi.org/10.1182/blood-2023-178205

Published: 2023

Journal Articles

Optimizing Albuminuria Assessment in Patients with Sickle Cell Disease: Insights from the Sikamic Study

Pablo Bartolucci, Saliou Diop, Aurélien Yapi, Giovanna Cannas, Gonzalo De Luna, Maryse Etienne-Julan, Jean-Benoit Arlet, Stephanie Ngo, Emmanuelle Bernit, Justine Gellen-Dautremer, Gylna Loko, Stanislas Nimubona, Maximilien Grall, Pierre Cougoul, Aldiouma Guindo, Vincent Audard

Blood (2023) 142 (Supplement 1): 1140.

https://doi.org/10.1182/blood-2023-180592

Published: 2023

Journal Articles

Hydroxyurea Is Associated with Later Onset of Occurrence of Acute Splenic Sequestration Episodes in Sickle Cell Disease: Lessons from the European Sickle Cell Disease Cohort - Hydroxyurea (ESCORT-HU) Study

Mariane de Montalembert, Frédéric Galactéros, Lena Oevermann, Giovanna Cannas, Laure Joseph, Gylna Loko, Narcisse Elenga, Malika Benkerrou, Maryse Etienne-Julan, Marie-Pierre Castex, Regine Grosse, Valentine Brousse

Blood (2022) 140 (Supplement 1): 449–450.

https://doi.org/10.1182/blood-2022-165946

Published: 2022

Journal Articles

Implementation of Escort-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study : Interests and Methodology

Mariane de Montalembert, Ersi Voskaridou, Lena Oevermann, Giovanna Cannas, Anoosha Habibi, Gylna Loko, Laure Joseph, Raffaella Colombatti, Pablo Bartolucci, Valentine Brousse, Frédéric Galactéros

Blood (2021) 138 (Supplement 1): 3098.

https://doi.org/10.1182/blood-2021-152525

Published: 2021

Journal Articles

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Frédéric Galactéros, MDPhD, Ersi Voskaridou, Anoosha Habibi, MD PhD, Giovanna Cannas, MD, Laure Joseph, MD, Gylna Loko, MD, Mariane De Montalembert, MD PhD, Narcisse Elenga, MD PhD, Malika Benkerrou, MD

Blood (2020) 136 (Supplement 1): 4–5.

https://doi.org/10.1182/blood-2020-140265

Published: 2020

Journal Articles

Sickle-Cell Disease Patients' Attitudes Towards Their Treatment with Hydroxycarbamide

Frédéric Galactéros, MD PhD, Ersi Voskaridou, Anoosha Habibi, Giovanna Cannas, MD, Laure Joseph, MD, Stephanie Ngo, MD, Nathalie Lemonne, Emmanuelle Bernit, MD, Justine Gellen-Dautremer, MD, Gylna Loko, MD

Blood (2019) 134 (Supplement_1): 1013.

https://doi.org/10.1182/blood-2019-125673

Published: 2019

Journal Articles

Outcomes of Pregnancies in Patients with Sickle-Cell Disease : Update from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Frédéric Galactéros, MD PhD, Giovanna Cannas, MD, Pablo Bartolucci, MD PhD, Ersi Voskaridou, Laure Joseph, MD, Emmanuelle Bernit, MD, Justine Gellen-Dautremer, MD, Corinne Charneau, MD, Stephanie Ngo, MD, Anoosha Habibi

Blood (2019) 134 (Supplement_1): 891.

https://doi.org/10.1182/blood-2019-125812

Published: 2019

Journal Articles

Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide

Anoosha Habibi, MD, Elena Foïs, MD, Giovanna Cannas, MD, Jean-Antoine Ribeil, MD, Pierre Cougoul, MD, Emmanuelle Bernit, MD, Pablo Bartolucci, MD PhD, Frederic Galacteros, MDPhD

Blood (2017) 130 (Supplement 1): 2260.

https://doi.org/10.1182/blood.V130.Suppl_1.2260.2260

Published: 2017

Journal Articles

Hydroxycarbamide (HU), Sickle Cell Disease and Pregnancy, a Multicentric Retrospective Study

Laure Joseph, MD, Anoosha Habibi, MD, Giovanna Cannas, MD, Stephanie Ngo, MD, Sylvain Le Jeune, MD, Ersi Voskaridou, MD, Elena Foïs, MD, Caroline Makowski, MD, Nathalie Lemonne, MD, Narcisse Elenga, MD, Yves Ville, MD PhD, Alexandra Benachi, MDPhD, Robert Girot, MD, Marina Cavazzana, MD PhD, Jean-Antoine Ribeil, MD PhD

Blood (2016) 128 (22): 1309.

https://doi.org/10.1182/blood.V128.22.1309.1309

Published: 2016

Journal Articles

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

Mauricette Michallet, MD PhD, Mohamad Sobh, Pharm.M., Aline Praire, MSc, Frederic Garban, MD PhD, Claude Eric Bulabois, MD, Ibrahim Yakoub-Agha, MD PhD, Valerie Coiteux, MD, Remy Dulery, MD, Pierre-Simon Rohrlich, MDPhD, Faezeh Legrand, MD, Laurence Clement, Stephane Morisset, Stat., Giovanna Cannas, MD, Marie Y. Detrait, MD, Fiorenza Barraco, MD, Franck E. Nicolini, MD PhD, Olivier Hequet, MD

Blood (2014) 124 (21): 3916.

https://doi.org/10.1182/blood.V124.21.3916.3916

Published: 2014

Journal Articles

The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens

Marie Y. Detrait, MD, Valerie Dubois, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Nathalie Tedone, CRA, Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Lilia Gillis, MD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Mauricette Michallet

Blood (2011) 118 (21): 2038.

https://doi.org/10.1182/blood.V118.21.2038.2038

Published: 2011

Journal Articles

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Marie Y. Detrait, MD, Patrice Chevallier, MD, PhD, Mohamad Sobh, Pharm.M., Thierry Guillaume, Xavier Thomas, MD, PhD, Stephane Morisset, Stat., Nathalie Tedone, CRA, Jacques Delaunay, MD, Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Youcef Chelghoum, MD, Mohamad Mohty, Mauricette Michallet

Blood (2011) 118 (21): 1957.

https://doi.org/10.1182/blood.V118.21.1957.1957

Published: 2011

Journal Articles

Highly Significant Impact of HLA-DRB3 and HLA-DRB4 Matching on Different Unrelated Allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Marie Y. Detrait, MD, Valerie Dubois, MD, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Franck E. Nicolini, MD, PhD, Helene Labussiere, MD, Fiorenza Barraco, MD, Giovanna Cannas, MD, Sophie Ducastelle, MD, Jihane Fattoum, MD, PhD, Xavier Thomas, MD, PhD, Youcef Chelghoum, MD, Nathalie Tedone, CRA, Sylvie Rey, Mauricette Michallet

Blood (2011) 118 (21): 4481.

https://doi.org/10.1182/blood.V118.21.4481.4481

Published: 2011

Journal Articles

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,

Mauricette Michallet, Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Helene Labussiere, MD, Marie Y. Detrait, MD, Sophie Ducastelle, MD, Fiorenza Barraco, MD, Jihane Fattoum, MD, PhD, Nathalie Tedone, CRA, Youcef Chelghoum, MD, Giovanna Cannas, MD, Xavier Thomas, MD, PhD, Franck E. Nicolini, MD, PhD

Blood (2011) 118 (21): 4093.

https://doi.org/10.1182/blood.V118.21.4093.4093

Published: 2011

Journal Articles

Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs)

David Sibon, Giovanna Cannas, Fiorenza Barraco, Thomas Prebet, M.D., Ph.D., Norbert Vey, MD, Anne Banos, MD, Caroline Besson, Selim Corm, Michel Blanc, Borhane Slama, Hervé Perrier, Pierre Fenaux, MD, PhD, Eric Wattel

Blood (2010) 116 (21): 4002.

https://doi.org/10.1182/blood.V116.21.4002.4002

Published: 2010

Journal Articles

Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma

Mohamad Sobh, Pharm.M., Stephane Morisset, Stat., Taoufik Guilli, MSc, Sophie Ducastelle-Lepretre, MD, Fiorenza Barraco, MD, Youcef Chelghoum, MD, Giovanna Cannas, MD, Xavier Thomas, MD, PhD, Aline Praire, MSc, Helene Labussiere, MD, Franck E Nicolini, MD, PhD, Colette Chapuis-Celier, MD, Mauricette Michallet, MD, PhD

Blood (2010) 116 (21): 2954.

https://doi.org/10.1182/blood.V116.21.2954.2954

Published: 2010

NARROW

Outcome of Cerebral Vasculopathy and Cognitive Performances 10 Years Post-Enrollment in the Drepagreffe Trial Comparing Allogeneic Stem Cell Transplantation to Standard-Care in Children with Sickle Cell Anemia and History of Abnormal Cerebral Velocities

ENERGIZE-T: A Global, Phase 3, Double-Blind, Randomized, Placebo-Controlled Study of Mitapivat in Adults with Transfusion-Dependent Alpha- or Beta-Thalassemia

Leg Ulcers in Sickle Cell Disease Patients Undergoing Hydroxyurea Therapy: Insights from Two Large Cohort Studies

Puberty Onset and Preservation of Fertility in Male Patients with Sickle Cell Disease Treated with Hydroxyurea: Data from the European Sickle Cell Disease Cohort - Hydroxyurea Extension (ESCORT-HU Extension) Study

Double-Blind Randomized Study to Evaluate the Effect of Hydroxycarbamide on Albuminuria in Adults with Sickle Cell Disease: Sikamic (SIklos on Kidney Function and AlbuMInuria Clinical Trial)

Optimizing Albuminuria Assessment in Patients with Sickle Cell Disease: Insights from the Sikamic Study

Hydroxyurea Is Associated with Later Onset of Occurrence of Acute Splenic Sequestration Episodes in Sickle Cell Disease: Lessons from the European Sickle Cell Disease Cohort - Hydroxyurea (ESCORT-HU) Study

Implementation of Escort-HU Extension: European Sickle Cell Disease Cohort - Hydroxyurea - Extension Study : Interests and Methodology

Is There a Clinical Benefit to Switch Hydroxyurea (HU) Drug in Sickle Cell Disease (SCD)?

Sickle-Cell Disease Patients' Attitudes Towards Their Treatment with Hydroxycarbamide

Outcomes of Pregnancies in Patients with Sickle-Cell Disease : Update from European Non-Interventional, Multicentric, Prospective Escort-HU Study

Management of Male Fertility in Sickle Cell Disease before and after Hydroxycarbamide

Hydroxycarbamide (HU), Sickle Cell Disease and Pregnancy, a Multicentric Retrospective Study

Prophylactic Extracorporeal Photopheresis for Gvhd Prevention after Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation from Identical Siblings and 10/10 HLA Unrelated Hematopoietic Stem Cells Donors

The Impact of Anti-HLA Antibodies on Allogeneic Hematopoietic Stem Cell Transplantation Outcomes After Reduced-Intensity Conditioning Regimens

Outcome of High-Risk and Refractory AML/MDS Patients Receiving a FLAMSA Sequential Chemotherapy Regimen Followed by Reduced-Intensity Conditioning (RIC) and Allogeneic Hematopoeitic Stem Cell Transplantation (allo-HSCT)

Highly Significant Impact of HLA-DRB3 and HLA-DRB4 Matching on Different Unrelated Allo-HSCT Outcomes: New Perspectives in the Unrelated Donor Selection

Relapse After Allogeneic Hematopoietic Stem Cell Transplantation in Hematological Malignancies: Factors Impacting Its Occurrence and Treatment Options for a Better Management,

Lenalidomide (LEN) In Lower-Risk Myelodysplastic Syndromes (MDS) with Karyotypes Other Than Deletion 5q and Refractory to Erythropoiesis-Stimulating Agents (ESAs)

Serum Kappa/Lambda Ratio, An Independent Prognostic Factor at Diagnosis and Serum Free-Light Chains Level, An Early Indicator of Relapse/Progression In Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only